

Vivli Clinical Research Data Sharing: Share. Discover. Innovate.

SOUNDING BOARD

Data Sharing from Clinical Trials — A Research Funder's Perspective

"...collaboration and cooperation among members of the global research community will be essential in maximizing the effect of funded research. It is simply unacceptable that the data from published clinical trials are not made available to researchers and used to their fullest potential to improve health."

Wellcome Trust, the UK Medical Research Council, Cancer Research UK, and the Bill and Melinda Gates Foundation.

n engl j med 377;20 nejm.org November 16, 2017



Current Gaps



Insufficient capacity to host data

Duplication of effort

Limited analytic tools and

environments

Global neutral data sharing and analytics platform



Creation of Vivli

Vivli was created through a project of the Multi-Regional Clinical Trials Center (MRCT Center) of Brigham and Women's Hospital and Harvard.

Supporters and funders of this project (in alphabetical order):

- Deloitte Consulting
- GlaxoSmithKline
- Doris Duke Charitable Foundation
- Helmsley Charitable Trust
- Institute of Medicine (now National Academies of Medicine)

- Johnson & Johnson
- Laura and John Arnold Foundation
- Lyda Hill Foundation
- Pfizer Foundation
- Wellcome Trust

And the volunteer efforts of over 150 individuals



Main Pain Points Addressed by Vivli

- Hosting and anonymizing data for data contributors as needed;
- Coordinating and harmonizing existing data-sharing initiatives, policies, and processes;
- 3) Enabling aggregation of data from multiple contributors;
- Access to secure full-featured analytic environment and tools;
- Sustainability for both data contributors and researchers





Introducing Vivli

THE ENTITY

- Vivli is a Massachussetts-based nonprofit 501(c)(3) organization
- Convening function
 - Biomedical industry (pharma, bio, device)
 - Academia
 - Non-profit funders and foundations
 - Government (funders and regulators)
 - Patient/patient advocates
- Governance and policy
 - Harmonizing language & agreements
 - Move culture of data sharing
- Advocacy
 - Lowering barriers
 - Promoting incentives
- Oversight of Implementation

THE VIVLI PLATFORM

- A user-friendly, secure, state-of-theart data sharing and analytics platform
- Serving the international community, including trials from any disease, country, sponsor, funder or investigator
 - Open search
 - Robust security
 - Modern tools and technologies



Critical Three-Part Solution

- Sustainability: Independent non-profit bringing together multiple stakeholders in a trusted, neutral broker under transparent shared governance
- Policy: Harmonized policies and streamlined processes for data submission, data request, data access, and sharing of academic credit
- Technology: Powerful comprehensive global data-sharing and analytics platform










The Vivli Platform










0 Results





0 Results



Log In



User can easily reclassify a term into a different PICO category



Does Rivastigmine treat **Dementia** in Parkinson's Disease



Parkinson's Disease

Parkinson's Disease Aggravated

Parkinson's Disease And Parkinsonism

Parkinson's Disease Clinic

Parkinson's Disease Nos

50 Results









does anticholinesterases treat Dementia in Parkinson's Disease





218 studies found matching your criteria

Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease

Query Terms Matching this Trial: Parkinson's Disease, Drug: Donepezil

Vivli ID: #123456789-02

Principal Investigator: Jack Frost, PhD

Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

Query Terms Matching this Trial: Parkinson's Disease Dementia, Drug: Rivastigmine capsule; Drug: Rivastigmine transdermal patch

Vivli ID: #123456789-02

Principal Investigator: Jack Frost, PhD

Sponsor: Novartis

Mild Cognitive Impairment in Parkinson's Disease

Query Terms Matching this Trial: Parkinson's Disease; Mild Cognitive Impairment, Drug: Exelon Patch (rivastigmine transdermal

system); Drug: Placebo Patches

Vivli ID: #123456789-02

Principal Investigator: Jack Frost, PhD

Sponsor: University of Pennsylvania

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Query Terms Matching this Trial: Dementia With Parkinson's Disease, Drug: ARICEPT

Vivi ID: #123456789-02

Principal Investigator: Jack Frost, PhD

Sponsor: Eisai Limited; Eisai Inc.


The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia

Query Terms Matching this Trial: Parkinson's Disease, Drug: Donepezil

Vivli ID: #123456789-02

Principal Investigator: Jack Frost, PhD

Sponsor: Inje Universit



Request Study 🗸

View Details

Request Study 🗸

View Details


Request Study V

View Details

Request Study

View Details

Launch Activities



- Preview MVP at MRCT Annual Meeting, December 6, 2017
- Public beta release and additional features (post-MVP) in Q2
- Formal Launch planned July 2018



Summary

- Time has come for IPD data sharing at a global scale
- Vivli operationalizes objectives, principles, and recommendations from previous groupings and events from around the world
- Provides standards-enabled data-sharing capacity to catalyze evolution of clinical research towards effective culture of data sharing and reuse

http://vivli.org/

